GRP and DPP4

Data Source:
HPRD (in vitro)

		GRP	DPP4
Description		gastrin releasing peptide	dipeptidyl peptidase 4
Image
GO Annotations	Cellular Component	Extracellular Region Extracellular Space Secretory Granule Lumen	Extracellular Region Lysosomal Membrane Plasma Membrane Focal Adhesion Cell Surface Membrane Integral Component Of Membrane Apical Plasma Membrane Lamellipodium Endocytic Vesicle Lamellipodium Membrane Membrane Raft Intercellular Canaliculus Extracellular Exosome
	Molecular Function	Signaling Receptor Binding Neuropeptide Hormone Activity Protein Binding	Virus Receptor Activity Protease Binding Aminopeptidase Activity Serine-type Endopeptidase Activity Signaling Receptor Binding Protein Binding Serine-type Peptidase Activity Dipeptidyl-peptidase Activity Identical Protein Binding Protein Homodimerization Activity Chemorepellent Activity
	Biological Process	Signal Transduction G Protein-coupled Receptor Signaling Pathway Neuropeptide Signaling Pathway Social Behavior Psychomotor Behavior Response To External Biotic Stimulus Positive Regulation Of Peptide Hormone Secretion Positive Regulation Of Phospholipase C-activating G Protein-coupled Receptor Signaling Pathway	Behavioral Fear Response Response To Hypoxia Proteolysis Cell Adhesion Positive Regulation Of Cell Population Proliferation Negative Regulation Of Extracellular Matrix Disassembly T Cell Costimulation Regulation Of Cell-cell Adhesion Mediated By Integrin Locomotory Exploration Behavior Psychomotor Behavior T Cell Activation Endothelial Cell Migration Viral Entry Into Host Cell Regulation Of Insulin Secretion Negative Chemotaxis Negative Regulation Of Neutrophil Chemotaxis
Pathways		Peptide ligand-binding receptors Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) G alpha (q) signalling events	Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
Drugs			Atorvastatin Sitagliptin 2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One 5-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-Amine (2s)-Pyrrolidin-2-Ylmethylamine 4-Iodo-L-phenylalanine Diisopropylphosphono Group 1-(1-phenylcyclopentyl)methylamine (S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide Vildagliptin PSN9301 AMG-222 Bisegliptin Alogliptin Saxagliptin (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-PROP-1-YN-1-YLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE N-(TRANS-4-{(1S,2S)-2-AMINO-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-1-METHYL-3-OXOPROPYL}CYCLOHEXYL)-N-METHYLACETAMIDE (2S,3S)-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine (2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine (3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amine (7R,8R)-8-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydroimidazo[1,2-a:4,5-c']dipyridin-7-amine (2S,3S)-3-{3-[4-(METHYLSULFONYL)PHENYL]-1,2,4-OXADIAZOL-5-YL}-1-OXO-1-PYRROLIDIN-1-YLBUTAN-2-AMINE (1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE (2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE (2S,3S)-3-AMINO-4-(3,3-DIFLUOROPYRROLIDIN-1-YL)-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YLCYCLOHEXYL)BUTANAMIDE (2S,3S)-3-AMINO-4-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-5-YLCYCLOHEXYL)BUTANAMIDE (3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-METHYL-1,4-DIAZEPAN-2-ONE 4'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide (2R,3R)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine 7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1H-benzimidazole-5-carbonitrile 4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one METHYL 4-{[({[(2R,5S)-5-{[(2S)-2-(AMINOMETHYL)PYRROLIDIN-1-YL]CARBONYL}PYRROLIDIN-2-YL]METHYL}AMINO)CARBONYL]AMINO}BENZOATE (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-ETHYNYLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE 1-biphenyl-2-ylmethanamine (1S,3S,5S)-2-{(2S)-2-amino-2-[(1R,3S,5R,7S)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile (2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDE (3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDE (4R,5R)-5-AMINO-1-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-2-ONE (3R,4S)-1-(3,4-DIMETHOXYPHENYL)-3-(3-METHYLPHENYL)PIPERIDIN-4-AMINE 1-[2-(S)-AMINO-3-BIPHENYL-4-YL-PROPIONYL]-PYRROLIDINE-2-(S)-CARBONITRILE ABT-341 (2R)-4-(2-BENZOYL-1,2-DIAZEPAN-1-YL)-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE (3R,4R)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-3-AMINE Gosogliptin N-({(2S)-1-[(3R)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide (3R,4S)-1-[6-(6-METHOXYPYRIDIN-3-YL)PYRIMIDIN-4-YL]-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE 6-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUM 7-BENZYL-1,3-DIMETHYL-8-PIPERAZIN-1-YL-3,7-DIHYDRO-PURINE-2,6-DIONE 2-({2-[(3R)-3-AMINOPIPERIDIN-1-YL]-4-OXOQUINAZOLIN-3(4H)-YL}METHYL)BENZONITRILE 4-[(3R)-3-{[2-(4-FLUOROPHENYL)-2-OXOETHYL]AMINO}BUTYL]BENZAMIDE 2-({8-[(3R)-3-AMINOPIPERIDIN-1-YL]-1,3-DIMETHYL-2,6-DIOXO-1,2,3,6-TETRAHYDRO-7H-PURIN-7-YL}METHYL)BENZONITRILE Linagliptin Dutogliptin
Diseases
GWAS		Adult body size ( 32376654) BMI (adjusted for smoking behaviour) ( 28443625) BMI in non-smokers ( 28443625) Body mass index ( 25673413) Body mass index (joint analysis main effects and smoking interaction) ( 28443625) Medication use (drugs used in diabetes) ( 31015401) Pancreatic cancer ( 29422604 26098869) Pancreatic ductal adenocarcinoma ( 30541042) Triglyceride levels x thiazide or thiazide-like diuretics use interaction ( 31806883) Type 2 diabetes ( 30297969) Venous thromboembolism ( 32232851)	Asthma ( 32296059) Blood osmolality (transformed sodium) ( 28360221) Brain morphology (min-P) ( 32665545) Brain morphology (MOSTest) ( 32665545) Cognitive ability ( 29186694) Cognitive ability (MTAG) ( 29186694) Cortical surface area (MOSTest) ( 32665545) Cortical thickness (MOSTest) ( 32665545) Dentate gyrus molecular layer volume ( 30279459) General cognitive ability ( 29844566) Hippocampal tail volume ( 30279459) Hippocampal tail volume (corrected for total hippocampal volume) ( 30279459) Hippocampal volume ( 22504421) Intelligence (MTAG) ( 29326435) Multiple sclerosis ( 31604244) Reaction time ( 29844566) Regular attendance at a pub or social club ( 29970889) Rheumatoid arthritis ( 24782177) Schizophrenia ( 25056061 29483656) Smoking initiation (ever regular vs never regular) ( 30679032) Smoking status (ever vs never smokers) ( 30643258) Subcortical volume (min-P) ( 32665545) Subcortical volume (MOSTest) ( 32665545) Subiculum volume ( 30279459) Total hippocampal volume ( 30279459) Tourette syndrome ( 30818990)
Interacting Genes		5 interacting genes: ALX1 DPP4 GRPR MEP1A MEP1B	16 interacting genes: ADA CCL11 CCL22 CCL3L1 CCL5 CD4 CPAMD8 CXCL10 CXCL11 CXCL12 CXCL9 CXCR4 DKK1 FAP GRP PTPRC
Entrez ID		2922	1803
HPRD ID		08845	02187
Ensembl ID		ENSG00000134443	ENSG00000197635
Uniprot IDs		A0A140VJM7 P07492	P27487
PDB IDs		2N0B 2N0C 2N0D 2N0E 2N0F 2N0G 2N0H	1J2E 1N1M 1NU6 1NU8 1PFQ 1R9M 1R9N 1RWQ 1TK3 1TKR 1U8E 1W1I 1WCY 1X70 2AJL 2BGN 2BGR 2BUB 2FJP 2G5P 2G5T 2G63 2HHA 2I03 2I78 2IIT 2IIV 2JID 2OAG 2OGZ 2OLE 2ONC 2OPH 2OQI 2OQV 2P8S 2QJR 2QKY 2QOE 2QT9 2QTB 2RGU 2RIP 3BJM 3C43 3C45 3CCB 3CCC 3D4L 3EIO 3F8S 3G0B 3G0C 3G0D 3G0G 3H0C 3HAB 3HAC 3KWF 3KWJ 3NOX 3O95 3O9V 3OC0 3OPM 3Q0T 3Q8W 3QBJ 3SWW 3SX4 3VJK 3VJL 3VJM 3W2T 3WQH 4A5S 4DSA 4DSZ 4DTC 4G1F 4J3J 4JH0 4KR0 4L72 4LKO 4N8D 4N8E 4PNZ 4PV7 4QZV 5I7U 5ISM 5J3J 5KBY 5T4B 5T4E 5T4F 5T4H 5Y7H 5Y7J 5Y7K 5ZID 6B1E 6B1O
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?